At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed invasive breast cancer, pT1-3; pNX, pN0-2 or pN3 (only when 10+ involved axillary lymph nodes); M0
- ✓Completely resected primary tumor, last surgery 3 weeks to 3 months before entry (if no chemotherapy) or 3 weeks to 3 months after chemotherapy
- ✓Estrogen receptor- and/or progesterone receptor-positive by immunohistochemistry or tumor receptor content ≥10 fmol/mg protein
- ✓Postmenopausal status: >60 years, OR age 45-59 with ≥1 year spontaneous menstrual cessation, OR age 45-59 with FSH in postmenopausal range, OR bilateral oophorectomy
- ✕Metastases confirmed by imaging (bone scan, abdominal ultrasound/CT, or chest x-ray as indicated)
- ✕Locally recurrent disease
- ✕Prior or concurrent carcinoma in situ of contralateral breast treated with partial mastectomy and/or hormonal therapy
- ✕Metachronous breast cancer
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer
In Brief
A Phase 3 clinical trial evaluating anastrozole and exemestane for Breast Cancer. Completed, enrolled 7,576 participants across 39 sites.
Detailed Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy, using exemestane or anastrozole, may fight breast cancer by reducing the production of estrogen. It is not yet known whether exemestane is more effective than anastrozole in preventing the recurrence of breast cancer. PURPOSE: This randomized phase III trial is studying exemestane to see how well it works compared to anastrozole in preventing cancer recurrence in postmenopausal women who have undergone surgery for primary breast cancer.
Study Details
Timeline
Interventions
Given orally
Given orally